Product Information
CYCLOBENZAPRINE ER 30 MG CAP is a generic product labeled by Upsher-Smith Laboratories LLC, priced at $0.8926 per EA under NDC 24979003604. Its NADAC has been published 123 times since Apr 17, 2024.
FDA first approved this application on Jan 31, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Cyclobenzaprine Hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30 mg/1
Manufacturer
Upsher-Smith Laboratories LLCNDC
24979003604
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
CYCLOBENZAPRINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA091281FDA Approved
1/31/2013
TE Code
AB
On Market Since
3/1/2019
Pharmacological Classes
Price Statistics
The NADAC for CYCLOBENZAPRINE ER 30 MG CAP has been published 123 times since Apr 17, 2024, and over the history we have for it it has declined 51.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8926 per EA |
|---|---|
| All-time high | $2.7621 (Jan 14, 2026) |
| All-time low | $0.8448 (Mar 18, 2026) |
| 52-week high | $2.7621 |
| 52-week low | $0.8448 |
| Median price | $1.8550 |
| Average price | $2.0217 |
| Largest weekly change | -69.0% (Jan 21, 2026) |
| Weeks tracked | 123 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CYCLOBENZAPRINE ER 30 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for CYCLOBENZAPRINE ER 30 MG CAP, manufactured by Upsher-Smith Laboratories LLC, is $0.8926 per EA (NDC 24979003604), effective Aug 19, 2026.
How has the price of CYCLOBENZAPRINE ER 30 MG CAP changed over time?
Over the history we have for it, the NADAC for CYCLOBENZAPRINE ER 30 MG CAP has declined 51.9%. It has been tracked across 123 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for CYCLOBENZAPRINE ER 30 MG CAP?
Since Apr 17, 2024, the NADAC for CYCLOBENZAPRINE ER 30 MG CAP has ranged from a low of $0.8448 (Mar 18, 2026) to a high of $2.7621 (Jan 14, 2026), with a median of $1.8550 per EA.
Are there cheaper alternatives to CYCLOBENZAPRINE ER 30 MG CAP?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CYCLOBENZAPRINE ER 30 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures CYCLOBENZAPRINE ER 30 MG CAP?
CYCLOBENZAPRINE ER 30 MG CAP (NDC 24979003604) is labeled by Upsher-Smith Laboratories LLC, and CMS classifies it as a generic product.